Home / Data / Women's Health Trial Tracker Women's Health Trial Tracker Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.
Records 5,000
Last changed 08/26/2026
Update schedule 55 1 * * * UTC
Coverage 05/26/2000–08/25/2026 Record Record Date Vuga Group Change Status Recency Days Public Significance Score Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT 12/22/2015 INTERVENTIONAL unchanged 3,900.85 0 TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature 12/30/2015 INTERVENTIONAL unchanged 3,892.85 0 Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010) 12/30/2015 INTERVENTIONAL unchanged 3,892.85 0 Lateral Episiotomy or Not in Vacuum Assisted Delivery in Non-parous Women 12/30/2015 INTERVENTIONAL unchanged 3,892.85 0 Ovarian Tissue Cryopreservation in Children 01/05/2016 INTERVENTIONAL unchanged 3,886.85 0 Pain Control in Breast Surgery: Analgesia, Opioid Consumption and Inflammatory Response Evaluation 01/06/2016 INTERVENTIONAL unchanged 3,885.85 0 Improving Maternal and Child Health Through Prenatal Fatty Acid Supplementation 01/06/2016 INTERVENTIONAL unchanged 3,885.85 0 Acupuncture or Metformin for Insulin Resistance in Women With PCOS 01/06/2016 INTERVENTIONAL unchanged 3,885.85 0 Reprometabolic Syndrome Mediates Subfertility in Obesity 01/12/2016 INTERVENTIONAL unchanged 3,879.85 0 Women at Risk of Breast Cancer and OLFM4 01/12/2016 INTERVENTIONAL unchanged 3,879.85 0 Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) 01/12/2016 OBSERVATIONAL unchanged 3,879.85 0 The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer 01/12/2016 INTERVENTIONAL unchanged 3,879.85 0 A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy 01/13/2016 INTERVENTIONAL unchanged 3,878.85 0 Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Infertility 01/15/2016 INTERVENTIONAL unchanged 3,876.85 0 Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation 01/20/2016 INTERVENTIONAL unchanged 3,871.85 0 Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer 01/20/2016 INTERVENTIONAL unchanged 3,871.85 0 Apical Suspension Repair for Vault Prolapse In a Three-Arm Randomized Trial Design 02/09/2016 INTERVENTIONAL unchanged 3,851.85 0 Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA 02/18/2016 INTERVENTIONAL unchanged 3,842.85 0 Vitamin D Dynamics in Women 03/10/2016 OBSERVATIONAL unchanged 3,821.85 0 Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Severe Left Diaphragmatic Hernia (CDH) 03/17/2016 INTERVENTIONAL unchanged 3,814.85 0 Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer 03/18/2016 INTERVENTIONAL unchanged 3,813.85 0 A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction 03/31/2016 INTERVENTIONAL unchanged 3,800.85 0 Feasibility and Tolerability of Transcranial Direct Current Stimulation With Concurrent Cognitive Training 04/04/2016 INTERVENTIONAL unchanged 3,796.85 0 Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) 04/04/2016 INTERVENTIONAL unchanged 3,796.85 0 MRI-Based Preoperative Accelerated Partial Breast Irradiation 04/05/2016 INTERVENTIONAL unchanged 3,795.85 0 Standard Follow-up Program Cervix Cancer (SFP CERVIX) 04/11/2016 OBSERVATIONAL unchanged 3,789.85 0 Zambian Preterm Birth Prevention Study 04/14/2016 OBSERVATIONAL unchanged 3,786.85 0 Uterine Transplant in Absolute Uterine Infertility (AUIF) 04/18/2016 INTERVENTIONAL unchanged 3,782.85 0 Lymphedema Surveillance Study 04/19/2016 OBSERVATIONAL unchanged 3,781.85 0 DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer 04/20/2016 INTERVENTIONAL unchanged 3,780.85 0 Biobank on Prematurity, Preeclampsia and Other Pregnancy Complications 04/20/2016 OBSERVATIONAL unchanged 3,780.85 0 A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer 04/21/2016 INTERVENTIONAL unchanged 3,779.85 0 Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer 04/25/2016 INTERVENTIONAL unchanged 3,775.85 0 Breast Cancer WEight Loss Study (BWEL Study) 04/26/2016 INTERVENTIONAL unchanged 3,774.85 0 Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer 04/27/2016 INTERVENTIONAL unchanged 3,773.85 0 Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment 04/28/2016 INTERVENTIONAL unchanged 3,772.85 0 A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer 04/28/2016 INTERVENTIONAL unchanged 3,772.85 0 Trial to Compare Radiation Fibrosis With Five Versus Three Fractions 04/29/2016 INTERVENTIONAL unchanged 3,771.85 0 Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations 05/04/2016 INTERVENTIONAL unchanged 3,766.85 0 A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer 05/05/2016 INTERVENTIONAL unchanged 3,765.85 0 Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) 05/06/2016 INTERVENTIONAL unchanged 3,764.85 0 Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients 05/13/2016 OBSERVATIONAL unchanged 3,757.85 0 Gastroschisis Outcomes of Delivery (GOOD) Study 05/17/2016 INTERVENTIONAL unchanged 3,753.85 0 Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers 05/17/2016 INTERVENTIONAL unchanged 3,753.85 0 Apremilast Pregnancy Exposure Registry 05/17/2016 OBSERVATIONAL unchanged 3,753.85 0 Clinical Performance of B-Lite® Light Weight Breast Implant 05/19/2016 INTERVENTIONAL unchanged 3,751.85 0 Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer 05/20/2016 INTERVENTIONAL unchanged 3,750.85 0 Evaluating the Effects of Genetic Testing on Patients' Stress Levels 05/26/2016 OBSERVATIONAL unchanged 3,744.85 0 Understanding and Predicting Breast Cancer Events After Treatment 06/07/2016 INTERVENTIONAL unchanged 3,732.85 0 T-Cell Therapy for Advanced Breast Cancer 06/07/2016 INTERVENTIONAL unchanged 3,732.85 0
Source U.S. National Library of Medicine, ClinicalTrials.gov API v2 · official record · retrieved 08/26/2026 · upstream last modified 08/26/2026
Licence United States government work; public domain unless the source record says otherwise. Source: U.S. National Library of Medicine
Required notice Study records are informational and do not provide diagnosis, treatment advice, or an assessment of individual risk. What we add We compute Vuga Group, Change Status, Recency Days, Public Significance Score using the documented compute method. · methodology